Ashley Toye, co-founder and chief scientific officer of Scarlet Therapeutics, recently shared the story behind the company’s creation at the Advanced Therapies conference in London, UK. Speaking to delegates, Toye outlined a practical roadmap for transforming academic research into a successful cell therapy spinout, highlighting the importance of innovation, strategic planning, and collaboration.
Identifying the Problem and Building the Concept
According to Toye, every successful spinout begins with identifying a clear clinical or scientific need. In Scarlet Therapeutics’ case, the focus was on addressing the logistical challenges faced by blood services, including matching blood groups and maintaining a reliable blood supply.
Academic research at the University of Bristol allowed the team to explore solutions. At the same time, NHS Blood and Transplant (NHSBT) supported the effort through funding, enabling researchers to investigate methods for growing red blood cells in the laboratory.
Proof-of-concept experiments played a critical role in validating the idea. Toye emphasized that conducting early testing within academia can increase the chances of securing long-term funding and advancing the technology further.
Breakthrough in Engineered Red Blood Cells
As reported by bioxconomy, the project reached a turning point when researchers developed the ability to manipulate cells, express proteins, and generate immortalized progenitor cell lines. These advances enabled the creation of a scalable platform technology capable of producing therapeutic red blood cells (tRBCs) without relying on traditional blood donations.
As a result, the technology moved beyond academic experimentation and opened the path toward commercial development of engineered blood cell therapies.
Addressing Sickle Cell Disease and Blood Supply Challenges
Scarlet’s technology could significantly benefit patients with sickle cell disease, a genetic disorder that produces misshapen red blood cells and often requires frequent transfusions.
To address donor shortages, the company developed manufactured red blood cells designed to reduce reliance on traditional blood donations. The RESTORE clinical trial, led by Scarlet Therapeutics and sponsored by NHSBT, is currently evaluating how long engineered red blood cells survive in the human body.
If successful, this innovation could provide a new transfusion option while reducing dependency on donor matching, offering hope for patients who struggle to access compatible blood supplies.